Rebecca A. Gallego

机构：Pfizer (United States) · ORCID：0000-0001-7893-9032

发表论文 14 篇 · 总被引 496 次 · h-index 7

代表论文

• Lipophilic Efficiency as an Important Metric in Drug Design (2018 · Journal of Medicinal Chemistry · 被引 349)
• Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1 (2023 · Journal of Medicinal Chemistry · 被引 40)
• Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation (2019 · Journal of Biological Chemistry · 被引 31)
• Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer (2024 · Journal of Medicinal Chemistry · 被引 23)
• Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib (2018 · ACS Medicinal Chemistry Letters · 被引 23)
• An update on lipophilic efficiency as an important metric in drug design (2024 · Expert Opinion on Drug Discovery · 被引 11)